ACHC · Acadia Healthcare Company, Inc. · Stock research

Current Thesis

The turnaround that started printing in Q1 is drawing a fresh analyst re-rate. On 2026-07-09 UBS reiterated Buy and lifted its target to $39 up from $31 and, notably, above the $30.20 52-week high extending a cluster that already held UBS $31 (2026-04-17), RBC $31 (2026-05-04) and Jefferies $30 (2026-06-03). The operational base under that call is real: Q1 2026 (2026-04-29) revenue $828.8M (+7.6% YoY), acute inpatient psych $470.7M (+14% YoY), and a raised FY26 guide of revenue $3.37–3.45B / adj. EBITDA $580–615M / adj. EPS $1.35–1.60. With ~29% of the float short, a Q2 beat or a confirmed Florida Directed Payment Program benefit becomes covering fuel on top of fundamental buying. The counter-weight has not moved: an open DOJ/SEC investigation and a fresh $105M jury verdict (2026-05-12) are discrete, unresolved tail risks. The stock has already doubled off the $11.43 low and spent June digesting the mid-$20s; this is a MATURING recovery attempting a second leg into the ~2026-07-28 Q2 print, not a fresh breakout off a base.

Bullish and bearish views on Acadia Healthcare Company, Inc.

The model's bull view on Acadia Healthcare Company, Inc. (ACHC), in brief: UBS to $39 (2026-07-09): Buy reiterated, target raised from $31 to $39 the first sell-side number set above the $30.20 52-week high, signaling the Street now underwrites both the guide and the Florida DPP upside rather than just the bounce off the low. The bear view: $105M jury verdict (2026-05-12): subsidiary Fashion Valley CTC hit with $35M compensatory + $70M punitive in a retaliatory-termination case; management is pursuing post-trial motions and appeal but concedes no assurance damages are reduced. Both cases follow in full.

Bull Case

• UBS to $39 (2026-07-09): Buy reiterated, target raised from $31 to $39 the first sell-side number set above the $30.20 52-week high, signaling the Street now underwrites both the guide and the Florida DPP upside rather than just the bounce off the low.
• Clean Q1 + raised FY26 guide (2026-04-29): Revenue $828.8M (+7.6% YoY); same-facility revenue +7.3% (1.6% more patient days, 5.6% higher revenue/day); acute inpatient psych $470.7M (+14% YoY). FY26 guide lifted to revenue $3.37–3.45B / adj. EBITDA $580–615M / adj. EPS $1.35–1.60.
• Concrete Q2 bar: Management guided Q2 to revenue $835–850M / adj. EBITDA $142–152M / adj. EPS $0.30–0.40 a measurable line the ~2026-07-28 print is judged against, with Florida DPP the swing factor Jefferies flagged as a further guide-raise trigger.
• ~29% short interest: a heavily short float against a confirmed guide raise turns any Q2 beat or DPP approval into forced covering.
• Capacity + cash-conversion inflection: 275 facilities / ~12,400 beds across 40 states + Puerto Rico (2026-03-31), ~84,000 patients daily; 400–600 net new beds planned in 2026 while cutting capex $300M+ vs 2025. Two JV beds open in Q2 (144-bed with Orlando Health; 96-bed with Methodist Jennie Edmundson, Iowa).

Bear Case

• $105M jury verdict (2026-05-12): subsidiary Fashion Valley CTC hit with $35M compensatory + $70M punitive in a retaliatory-termination case; management is pursuing post-trial motions and appeal but concedes no assurance damages are reduced. Discrete from the federal probe.
• DOJ + SEC investigations remain open: unresolved per the 2025 annual report; $135M legal fees in 2025. A charging decision or consent decree is a single-session -20%+ tail. The closed 2024 ~$20M Medicare-fraud settlement did not resolve these.
• The easy 2x is done: from $11.43 to a ~$26.84 June high, then a fade back to $23.50 (2026-06-17). The mania leg off the low is over; further upside has to come from a guide raise rather than the multiple re-rating off distressed lows.
• UBS $39 sits above the whole range: it clears the prior $30–31 cluster and the 52-week high a target the tape has not yet validated, and one that already prices a Florida DPP benefit not yet in reported results.
• Earnings binary approaching: the ~2026-07-28 Q2 print is the whole thesis test; a guide held flat despite DPP, or any probe headline, resets the multiple fast.

Setup & Price Structure

The recovery structure is intact but extended. Off the $11.43 52-week low the stock ran to a ~$26.84 June high, faded the Jefferies upgrade day, and spent June building a tightening range in the mid-$20s (last confirmed $23.50 on 2026-06-17, market cap ~$2.25B, 52-week range $11.43–$30.20). The June low-$22 base (~$22.66) is the pivot that defines the recovery trend; the $20 handle is the line where the turnaround structure breaks entirely. To the upside, the shelf near $25 and the June high ~$26.84 are the levels a UBS-$39-driven second leg has to clear on volume a decisive reclaim of $27 opens air toward the old $30.20 high and then the analyst cluster. Absent a fresh Q2 catalyst the name has shown it mean-reverts inside the mid-$20s rather than trending, so strength here is best treated as a catalyst play into 2026-07-28, not a clean base breakout. The ~29% short interest cuts both ways: it accelerates a post-beat move but also amplifies air-pockets on any probe headline.

Catalyst Calendar (next 30 days)

• ~2026-07-28 (est.): Q2 2026 earnings the binary. Watch for a FY26 guide raise, the Florida DPP contribution, and any commentary on the DOJ/SEC timeline. 3-trading-day pre-print blackout applies (~from 2026-07-23).
• Through Q2/Q3: two JV facility openings ramp (144-bed Orlando Health; 96-bed Methodist Jennie Edmundson, Iowa) supply adds feeding the same-facility line.
• Undated but live: any DOJ/SEC charging or consent-decree 8-K; an appellate or post-trial ruling on the $105M Fashion Valley verdict; further sell-side moves following the UBS $39 reset.

What Would Change Our Mind

The bullish read depends on the recovery trend holding and the Q2 print confirming the guide. A weekly close below $22.66 loses the June recovery base and breaks the structure; losing the $20 handle confirms it and returns the name to value-trap territory. On the fundamental side, a DOJ/SEC charging decision or consent decree, the $105M verdict upheld or expanded on appeal, or a Q2 print that fails to raise guidance despite Florida DPP approval each invalidate the second-leg thesis regardless of price. Adding to a broken position lower here is the specific error to avoid the profile is a turnaround carrying unresolved legal tails, and a failed low-$20s base is exactly where it becomes a trap. A durable re-rate would need a clean weekly reclaim of the mid-$20s on volume plus the Q2 guide raise landing.

Correlation Notes

ACHC trades with the behavioral-health / managed-care services complex; UHS is the closest large-cap comp, and the psych-facility read-through overlaps with hospital-operator sentiment. The dominant macro sensitivities are Medicaid/Medicare rate policy and state Directed Payment Programs the Florida DPP is the current live example, and any adverse federal or state reimbursement headline hits the whole group. The DOJ/SEC overhang and the $105M verdict are idiosyncratic, so single-name legal risk can decouple it from the group on any given session. The ~29% short interest makes it a higher-beta expression of behavioral-health sentiment than its peers, over-moving the group in both directions.